


In the Claims:

Please cancel claims 29 to 45 without prejudice and add new claims 46 to 59 as follows:


Claims 1 to 45 (canceled).

46(new). An injectable liquid oligomer-polymer composition consisting of at least one bioactive substance, at least one solid polymeric hydroxycarboxylic acid ester and at least one liquid oligomeric hydroxycarboxylic acid ester.


47(new). The injectable liquid oligomer-polymer composition as defined in claim 46, wherein said at least one liquid oligomeric hydroxycarboxylic acid ester is an ester compound of formula I, an ester compound of formula II or an ester compound of formula III:



I



II



III

wherein R for variables m, n, o, p, q and r is identical or different and represents $-\text{CH}_2-$, $-\text{CH}(\text{CH}_3)-$, $-(\text{CH}_2)_5-$, $-\text{CH}_2-\text{CH}_2-\text{O}-\text{CH}_2-$ or $-\text{CH}_2-\text{CH}_2-\text{O}-\text{CH}_2-\text{CH}_2-\text{O}-\text{CH}_2-$, or homologues thereof with up to 5 further C atoms in each case;

wherein R_1 represents $-\text{CH}_2-\text{COOY}$, $-\text{CH}(\text{CH}_3)-\text{COOY}$, $-\text{CH}_2-\text{CH}_2-\text{COOY}$, $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{COOY}$, $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{COOY}$, $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{COOY}$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{Y}$, $-(\text{cyclo-C}_6\text{H}_{11})$ or $-\text{CH}_2-\text{C}_6\text{H}_5-$;

wherein R_2 represents $-\text{CH}_2-\text{CH}(\text{CH}_3)-$, $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$, $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$, $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$, $-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-$, $-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-$, $-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-$, $-\text{CH}_2-\text{CH}(\text{Y})-\text{CH}_2-$, cyclohexane-1,2-diyl, cyclohexane-1,3-diyl or cyclohexane-1,4-diyl;

wherein R_3 represents $(-\text{CH}_2)_2\text{CH}-$, $(-\text{CH}_2)_3\text{C}-\text{CH}_3$ or $(-\text{CH}_2)_3\text{C}-\text{CH}_2-\text{CH}_3$,

wherein Y is $-\text{H}$, $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$ or $-\text{C}_4\text{H}_9$, and m, n, o, p, q and r denote, independently of one another, an integer from 2 to 18.

48(new). The injectable liquid oligomer-polymer composition as defined in claim 47, wherein said R denotes said $-\text{CH}(\text{CH}_3)-$, said R_1 denotes said $-\text{CH}(\text{CH}_3)-\text{COOY}$ with said Y = said $-\text{C}_2\text{H}_5$, and said integer is 2, 3 or 4.

49(new). The injectable liquid oligomer-polymer composition as defined in claim 46, wherein the at least one liquid oligomeric hydroxycarboxylic acid ester is at least one poly(hydroxyester) and/or a copolymer thereof.

50(new). The injectable liquid oligomer-polymer composition as defined in claim 49, wherein said at least one poly(hydroxyester) is a poly(L-lactide), a poly(D,L-lactide), a poly(glycolide), a poly(caprolactone), a poly(dioxanone), a poly(hydroxybutyric acid), a poly-(hydroxyvaleric acid), a poly(glycosalicylate) and/or a product of ring-opening polymerization of a lactone in the presence of a biocompatible starter molecule.

51(new). The injectable liquid oligomer-polymer composition as defined in claim 50, wherein said biocompatible starter molecule is an alkyl L-lactide, cholesterol, propane-1, 2-diol, triethylene glycol, glycerol or pentaerythritol.

52(new). The injectable liquid oligomer-polymer composition as defined in claim 46, wherein said at least one solid polymeric hydroxycarboxylic acid ester and said at least one liquid oligomeric hydroxycarboxylic acid ester are present in a ratio of 1:100 to 1:1.

53(new). The injectable liquid oligomer-polymer composition as defined in claim 52, wherein said ratio is from 1:10 to 1:2.

54(new). The injectable liquid oligomer-polymer composition as defined in claim 46, wherein said at least one bioactive substance is selected from the group consisting of hormones, immunomodulators, immunosuppressants, antibiotics, cytostatics, diuretics, gastrointestinal agents, cardiovascular agents and

neuropharmaceuticals.

55(new). The injectable liquid oligomer-polymer composition as defined in claim 54, wherein said at least one bioactive substance is present in dissolved or suspended form.

56(new). An implant obtained by injecting the injectable liquid oligomer-polymer composition as defined in one of claims 46 to 55 into a mammal.

57(new). A method of preparing an implant for delivering at least one bioactive substance to a mammal, said method comprising the steps of:

a) preparing an injectable liquid oligomer-polymer composition consisting of at least one bioactive substance, at least one solid polymeric hydroxycarboxylic acid ester and at least one liquid oligomeric hydroxycarboxylic acid ester; and

b) injecting said injectable liquid oligomer-polymer composition in said mammal so as to form a coagulum under the influence of body fluid of said mammal.

58(new). The method as defined in claim 57, wherein said injectable liquid oligomer-polymer composition is defined in one of claims 47 to 55.

59(new). The coagulum prepared by the method as defined in claim 57.